Cardinal Health Inc. (CAH) News
Filter CAH News Items
CAH News Results
|Loading, please wait...|
CAH News Highlights
- For CAH, its 30 day story count is now at 20.
- Over the past 16 days, CAH's stories per day has been in a clear uptrend, growing by about 0.13 per day.
- CBOE, SAFE and AEO are the most mentioned tickers in articles about CAH.
Latest CAH News From Around the Web
Below are the latest news stories about CARDINAL HEALTH INC that investors may wish to consider to help them evaluate CAH as an investment opportunity.
Here is how Arch Therapeutics, Inc. (ARTH) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS therapy for lasting pain relief, enhanced function, quality of life and reduced opioid dependency.
Days after posting the Class 1 recall notice, the FDA said changes made to certain syringes could lead to overdose, underdose, or delays in therapy or alarms.
The U.S. Food and Drug Administration on Monday warned healthcare providers and facilities not to use Cardinal Health's Monoject syringes with patient-controlled pain management pumps and syringe pumps. The regulator's warning comes after Cardinal Health initiated a recall for its Monoject syringes due to incompatibility concerns with syringe pumps. Monoject syringes are used to inject into or withdraw fluids from the body while patient-controlled analgesia, or pain management pumps, are used to treat different kinds of pain by transferring medications intravenously.
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Cboe Global, Parker-Hannifin, Microsoft, FedEx and Cardinal Health have been highlighted in this Screen of The Week article.